Scientific Officer of Biodexa Pharmaceuticals PLC, expressed his satisfaction with the study's results. He emphasized that the study provided valuable insights into the safety and efficacy of intra-tumoral administration of MTX110 via CED. The success of this study has led to a follow-up Phase I study at Columbia University.